- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00540670
A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease
May 9, 2013 updated by: Eisai Co., Ltd.
The purpose of this study is to assess the safety and tolerability of E5555 in Japanese subjects with coronary artery disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
240
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Gifu, Japan
-
Kumamoto, Japan
-
Osaka, Japan
-
Saitama, Japan
-
Shizuoka, Japan
-
-
Aichi
-
Ichinomiya, Aichi, Japan
-
-
Gifu
-
Ogaki, Gifu, Japan
-
-
Hokkaido
-
Asahikawa, Hokkaido, Japan
-
Chitose, Hokkaido, Japan
-
Sapporo, Hokkaido, Japan
-
Tomakomai, Hokkaido, Japan
-
-
Hyogo
-
Himeji, Hyogo, Japan
-
Nishinomiya, Hyogo, Japan
-
-
Ibaraki
-
Tsuchiura, Ibaraki, Japan
-
-
Ishikawa
-
Kanazawa, Ishikawa, Japan
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan
-
-
Mie
-
Matsusaka, Mie, Japan
-
Tsu, Mie, Japan
-
-
Osaka
-
Osakasayama, Osaka, Japan
-
-
Saitama
-
Kitamoto, Saitama, Japan
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan
-
Musashino, Tokyo, Japan
-
Ota-ku, Tokyo, Japan
-
Shinjuku-ku, Tokyo, Japan
-
Tachikawa, Tokyo, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 45 - 80 years old (at time of informed consent).
- Male or female (females of childbearing potential must use contraception).
- Confirmed coronary artery disease.
- All subjects must be receiving aspirin (75 - 325 mg).
Exclusion Criteria:
- Unwilling or unable to provide informed consent.
- History of acquired or congenital bleeding disorder, coagulopathy, or platelet disorder.
- Recent trauma or major surgery.
- Evidence of active pathological bleeding or history of bleeding such as gastrointestinal or genitourinary, unless the cause has been definitely corrected.
- History of intracranial bleeding or history of hemorrhagic retinopathy.
- New York Heart Association class III or IV congestive heart failure.
- Pregnant or lactating women.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
E5555 50 mg (tablet) taken orally, once a day.
|
Experimental: 2
|
E5555 100 mg (tablet) taken orally, once a day.
|
Experimental: 3
|
E5555 200 mg (tablet) taken orally, once a day.
|
Placebo Comparator: 4
|
Placebo (tablet) taken orally, once a day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability: Adverse events, bleeding events, clinical laboratory tests, Coagulation tests, vital signs and 12-lead ECG
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Major cardiac adverse events, biomarkers, platelet aggregation inhibition, plasma concentration.
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Masaru Takeuchi, New Product Development, Clinical Research Center, Eisai Co., Ltd.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2007
Primary Completion (Actual)
March 1, 2009
Study Registration Dates
First Submitted
October 4, 2007
First Submitted That Met QC Criteria
October 4, 2007
First Posted (Estimate)
October 8, 2007
Study Record Updates
Last Update Posted (Estimate)
May 13, 2013
Last Update Submitted That Met QC Criteria
May 9, 2013
Last Verified
February 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- E5555-J081-206
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on E5555 50 mg
-
Eisai Inc.CompletedAcute Coronary SyndromeUnited Kingdom, United States
-
Eisai Inc.CompletedCoronary Artery DiseaseUnited States
-
Zydus Lifesciences LimitedRecruitingAmyotrophic Lateral SclerosisIndia
-
ViiV HealthcareGlaxoSmithKline; Janssen PharmaceuticalsCompletedInfection, Human Immunodeficiency VirusUnited States
-
Eisai Co., Ltd.CompletedAcute Coronary SyndromeJapan
-
Eisai Inc.Completed
-
Alcon ResearchCompletedNeovascular Age-Related Macular Degeneration
-
Sprout Pharmaceuticals, IncCompletedSexual Dysfunctions, PsychologicalAustria, Belgium, Czech Republic, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom
-
Eisai Inc.CompletedHealthy SubjectsUnited States
-
Eisai Korea Inc.RecruitingParkinson DiseaseKorea, Republic of